Conservation treatment of early breast cancer: Long term results and complications

Delouche, G; Bachelot, F.; Prémont, Marie-Claude; Kurtz, John M.

doi:10.1016/0360-3016(87)90256-2

Cited by 212 publications

(80 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These two reports are examples of quite different treatments policy, and show the range of survival rates that can be obtained after breast-conserving treatment. For disease-free survival, rates ranging from 75% to 90% after 5 years and from 69% to 75% after 10 years have been reported (15)(16)(17)(18)(19). The survival rates for our patients (93% survival after 5 years, 91% after 8 years, 87% and 85% metastasesfree survival after 5 and 8 years) are similar.…”

Section: Resultssupporting

confidence: 72%

Breast-Conserving Treatment of Early Breast Cancer Results in a common clinical trial

et al. 1993

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 72%

Breast-Conserving Treatment of Early Breast Cancer Results in a common clinical trial

et al. 1993

View full text Add to dashboard Cite

“…6,23,30,36±41 The appearance of this type of injury dictated a stepwise reduction in radiation dose and increasing fractionation throughout the sixties. 21,22 Since the early seventies the standard treatment policy of radiation therapy is a moderate doses (50 Gy) to the breast and locoregional lymph drainage area such as axilla and supraclavicular, with higher doses directed only to the tumor bed. 21 Radiation therapy only to the breast did not increase incidence of upper limb morbidity.…”

Section: Introductionmentioning

confidence: 99%

“…21,22 Since the early seventies the standard treatment policy of radiation therapy is a moderate doses (50 Gy) to the breast and locoregional lymph drainage area such as axilla and supraclavicular, with higher doses directed only to the tumor bed. 21 Radiation therapy only to the breast did not increase incidence of upper limb morbidity. 28 The incidence of late morbidity after breast cancer treatment: arm edema and reduced range of motion of the shoulder, varies widely due to differences in study population, surgical procedures, radiation dose and fractionation and assessment methods.…”

Section: Introductionmentioning

confidence: 99%

Late morbidity after treatment of breast cancer in relation to daily activities and quality of life: a systematic review

Rietman¹,

Dijkstra²,

Hoekstra³

et al. 2003

European Journal of Surgical Oncology (EJSO)

233

188

View full text Add to dashboard Cite

Aims: Breast cancer treatment may result in long-term upper limb morbidity: reduced range of motion of the shoulder, muscle weakness of the arm and hand, lymph edema, pain and numbness. Relationship of this late morbidity with activities of daily life (ADL) and quality of life (QOL) is infrequently described and the strength of this relationship is not clear. Methods: A systematic review was performed to evaluate the results of studies, analyzing late morbidity of breast cancer treatment in relationship with ADL and/or QOL. A literature search over the last 20 years (1980±2000) was performed in the databases MEDLINE, EMBASE, PSYCHLIT and CANCERLIT. Methodological quality of selected articles was assessed and additional, aspects of treatment related late morbidity and the relationship to ADL and/or QOL were summarized. Results: From the 1642 yielded articles 15 fulfilled our primary selection criteria. Only six articles could be selected due to the inappropriate methodological quality. There was high variation in prevalence of pain (12±51%), impairments in range of motion (2±51%), edema (6±43%) and decreased muscle strength (17±33%). Four articles reported significant relationships between late morbidity of the upper limb and perceived disabilities in ADL/QOL. The strength of these relationships was rather low. Conclusions: Few studies investigated the relationship between late morbidity of the upper limb after treatment of early breast cancer and ADL/QOL. Significant relationship between late morbidity and restrictions of daily activities and poorer QOL was reported, however, the strength of this relationship was rather low.

show abstract

“…Other explanations for the differences found were the woman's age at diagnosis (older women were less likely to undergo BCS) (Silliman et al, 1989;Cady and Stone, 1990;Farrow et al, 1992;Ganz, 1992;Satariano et al, 1992;Howe et al, 1995), geography (Cady and Stone, 1990;Ferguson et al, 1990;Farrow et al, 1992;Howe et al, 1995), and the availability of radiotherapy (Cady and Stone, 1990). Also, physician preference (Cady and Stone, 1990;Long, 1993), tumour size (Delouche et al, 1987;Cady and Stone, 1990;Margolese, 1995), the patient's own personal preferences (Cady and Stone, 1990), local medical customs and practices (Cady and Stone, 1990;Kiebert et al, 1991;Margolese, 1995), and co-morbidity (Satariano, 1992) all influence the choice of surgical procedure. Because we were able to use data on surgical procedures and length of stay from a national database, the treatment algorithms that we have developed incorporate the above-mentioned variations in practice patterns and surgical choices into the national average.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

et al. 1999

View full text Add to dashboard Cite

In an era of fiscal restraint, it is important to evaluate the resources required to diagnose and treat serious illnesses. As breast cancer is the major malignancy affecting Canadian women, Statistics Canada has analysed the resources required to manage this disease in Canada, and the associated costs. Here we report the cost of initial diagnosis and treatment of nonmetastatic breast cancer, including adjuvant therapies. Treatment algorithms for Stages I, II, and III of the disease were derived by age group (< 50 or ≥ 50 years old), principally from Canadian cancer registry data, supplemented, where necessary, by the results of surveys of Canadian oncologists. Data were obtained on breast cancer incidence by age, diagnostic work-up, stage at diagnosis, initial treatment, follow-up practice, duration of hospitalization and direct care costs. The direct health care costs associated with ‘standard’ diagnostic and therapeutic approaches were calculated for a cohort of 17 700 Canadian women diagnosed in 1995. Early stage (Stages I and II) breast cancer represented 87% of all incident cases, with 77% of cases occurring in women ≥ 50 years. Variations were noted in the rate of partial vs total mastectomy, according to stage and age group. Direct costs for diagnosis and initial treatment ranged from $8014 for Stage II women ≥ 50 years old, to $10 897 for Stage III women < 50 years old. Except for Stage III women < 50 years old, the largest expenditure was for hospitalization for surgery, followed by radiotherapy costs. Chemotherapy was the largest cost component for Stage III women < 50 years old. This report describes the cost of diagnosis and initial treatment of nonmetastatic breast cancer in Canada, assuming current practice patterns. A second report will describe the lifetime costs of treating all stages of breast cancer. These data will then be incorporated into Statistics Canada's Population Health Model (POHEM) to perform cost-effectiveness studies of new therapeutic interventions for breast cancer, such as the cost-effectiveness of day surgery, or of radiotherapy to all breast cancer patients undergoing breast surgery. © 1999 Cancer Research Campaign

show abstract

Conservation treatment of early breast cancer: Long term results and complications

Cited by 212 publications

References 11 publications

Breast-Conserving Treatment of Early Breast Cancer Results in a common clinical trial

Breast-Conserving Treatment of Early Breast Cancer Results in a common clinical trial

Late morbidity after treatment of breast cancer in relation to daily activities and quality of life: a systematic review

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

Contact Info

Product

Resources

About